Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
MD Start bucks the trend for later-stage medtech investing
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
Thrive emerges with cash, a cancer blood test, and a plan
A new player has entered the liquid biopsy game.
Looking back at April’s data digging and analysis
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
Corporate VC activity in medtech increases – until this year
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Venture funding slowdown continues in first quarter of 2019
Venture funding drops again, but there’s no need to panic yet.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Auris acquisition could prompt more mega VC rounds
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.